Stock Analiz

Universe Pharmaceuticals INC UPC

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.51Market cap $8M
Open the interactive analysis →

Universe Pharmaceuticals INC (UPC) is a healthcare company listed in the US with a market value of about $8M. In fiscal year 2025 it had revenue of $17.9B and net income of -$3.7B, a net margin of -20.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).

Key numbers: 5-year revenue growth of 257% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36537% above the current price.

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $33M in 2019 to $17.9B in 2025, growth of about 185.1% a year. It was profitable in 3 of the last 7 years in our data. It spends 4% of revenue on research and development.

Score: 1.2 / 5

Value1/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.0
P/B0.0
EV/EBITDA—
PEG—
Dividend yield—
FCF yield-70109.5%
Shareholder yield0.0%
Intrinsic value vs. price+36537%

Growth and quality

Revenue growth (1 yr)-22.4%
Revenue growth (5 yrs, per year)257.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-15.0%
ROIC (5-yr avg.)-1.1%
Profitable years (of last 10)3
Years paying a dividend1

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$17.9B$23.0B$32.3B$40M$48M$31M$33M
Net income-$3.7B-$8.7B-$6.6B-$8M$11M$8M$8M
Free cash flow-$5.3B-$9.7B$1.1B-$1M-$3M$6M$13M
EPS (diluted)$-730.85$-1737.00$-1310.00$-1.57$2.25$1.50$1.50
Net margin-20.6%-37.9%-20.4%-19.7%23.6%24.6%22.7%
ROIC-4.0%-12.3%-11.2%-0.0%21.9%32.7%61.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Universe Pharmaceuticals INC stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 36537% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Universe Pharmaceuticals INC pay a dividend?

Not currently.

Is Universe Pharmaceuticals INC a good stock to buy?

We do not give buy or sell advice. Universe Pharmaceuticals INC scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.